Skip to main
LNTH
LNTH logo

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc demonstrates a strong growth trajectory within its Precision Diagnostics and Radiopharmaceutical Oncology segments, indicated by an increase in POSLUMA's market share and revenue projections for PSMA PET imaging. The anticipated enhancements from the new Pylarify formulary, including a 50% increase in batch size and three years of TPT eligibility, are expected to reinvigorate growth from late 2026 onward, tapping into previously unmet demand. Additionally, potential growth and margin contributions from non-Pylarify segments may further bolster earnings, positively influencing the company's financial outlook for 2026 and beyond.

Bears say

Lantheus Holdings Inc is facing a negative outlook as it experiences slower growth compared to its profitable SMID MedTech peers, with projections for 2025-2026 indicating a decline in Pylarify revenue growth. The company's recent performance revealed a significant miss in Pylarify revenue, which totaled $260 million, reflecting an 8% year-over-year decrease and falling short by approximately $14 million against consensus estimates. Additionally, the overall unit growth was disappointing, registering only 2% year-over-year and facing a detrimental 10% price headwind during the quarter, further complicating its growth trajectory.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.